logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Halozyme Shares Spike on Breast Cancer Drug Recommendation

By  +Follow June 28, 2013 12:21PM
Share:
Tickers Mentioned:

Shares of Halozyme (HALO) spiked in afternoon trading june 28 after its partner Roche Holding AG (RHHBY) received a positive recommendation from a European advisory committee on its injectable form of Herceptin, a breast cancer drug.

According to Halozyme CEO Gregory Frost, a Phase 3 study on Herceptin indicated that the drug “may help decrease the time patients spend receiving treatment at a hospital or physician’s practice, by reducing the administration time.” Halozyme produces an enzyme for Herceptin that now allows it to be injected subcutaneously.

A typical IV infusion of Herceptin takes 30-90 minutes, but Herceptin can now be administered in just two to five minutes via injection under the skin. Roche is currently seeking European approval for the injectable drug, so the recommendation is a very encouraging sign.

“Pending European approval, this subcutaneous formulation of Herceptin will provide a new route of administration that could potentially save time for both physicians and HER2-positive breast cancer patients in Europe,” Frost said. The breakthrough could be a complete game changer in the breast cancer drug space, as treatments are usually time consuming for both patients and doctors.

Halozyme shares spiked during trading hours on June 28 when the news was released. The stock reached a daily high of $8.20, a gain of around 30 percent since close on June 27.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Signup for our daily newsletter and get our best articles emailed right to you!

				
				
By  +Follow June 28, 2013 12:21PM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

5 Small-Cap Energy with Hedges to Survive Oil's Bear Market


DraftKings and FanDuel: The New Face of Legalized Online Sports Betting

Is the Market Paying the Toll of Tech?

What Will Uber Look Like in the Future?


How Dodd-Frank Divides Political Parties Prior to 2016 Election

 

Apple (AAPL) is expected to announce its latest quarterly earnings next week. As the most valuable company by mark... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN